CTRI/2011/12/002189已完成4 期
To evaluate the safety and efficacy of fixed dose combination of Telmisartan and Amlodipine in hypertensive patients at risk of cardiovascular events. - Nil
Glenmark Pharmaceuticals Ltd0 个研究点目标入组 1,000 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •Uncontrolled hypertensives (BP more than 140/90 despite monotherapy with Telmisartan and Amlodipine
- •BP more than 130/80 mmHg for hypertensive patients with Diabetes
排除标准
- •Age below 18 years and above 75years
- •Secondary hypertension
- •Patients requiring concomitant anti-hypertensive medications other than angiotensin receptor blockers (ARBs) or Amlodipine
- •Uncontrolled diabetes mellitus
- •Pregnant women and lactating mothers
- •Females of child bearing age not practicing contraception or not willing to use barrier contraceptive
- •Known hypersensitivity to Telmisartan/Amlodipine
- •Patients with severe and or significant renal, hepatic or cardiac disease
- •Not willing to provide written informed consent and comply with the protocol
研究者
相似试验
已完成
4 期
A clinical trial to study the effects of two drugs Olmesartan and metoprolol in patients with high blood pressure and heart diseaseCTRI/2010/091/001438Glenmark Pharmaceuticals Limited1,000
招募中
4 期
A clinical trial to study the efficacy and tolerability of a combination of two topical drugs, minoxidil and aminexil in patients with male pattern hair lossCTRI/2009/091/001073Glenmark Pharmaceuticals Ltd204
进行中（未招募）
不适用
DOSE-FINDING STUDY TO ASSESS THE SAFETY AND EFFECT OF SYL1001 IN PATIENTS WITH OCULAR PAIEUCTR2014-004857-15-ESSylentis60
进行中（未招募）
1 期
DOSE-FINDING STUDY TO ASSESS THE SAFETY AND EFFECT OF SYL1001 IN PATIENTS WITH OCULAR PAIPatients with eye pain associated to dry eyeEUCTR2014-004857-15-EESylentis60
招募中
4 期
A Clinical Study to Evaluate the Safety and Efficacy of fixed dose combination of L-Ornithine-L-Aspartate 150 mg, Pancreatin IP 100mg enteric coated tablets as supportive and maintenance therapy in hepatitisCTRI/2022/06/043453Win Medicare Pvt Ltd